The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma von Horwitz, S., O'Connor, O.A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K.J., Yuen, S., Zinzani, P.L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T.

Volltext

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma von Connors, Joseph M, Jurczak, Wojciech, Straus, David J, Ansell, Stephen M, Kim, Won S, Gallamini, Andrea, Younes, Anas, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Oki, Yasuhiro, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Chen, Robert, Ramchandren, Radhakrishnan, Zinzani, Pier L, Cunningham, David, Rosta, Andras, Josephson, Neil C, Song, Eric, Sachs, Jessica, Liu, Rachael, Jolin, Hina A, Huebner, Dirk, Radford, John

Volltext

Technological capacity and firms’ recovery from Covid-19 von Doerr, S., Erdem, M., Franco, G., Gambacorta, L., Illes, A.

Volltext

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts von Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

Volltext

Development and Evaluation of a Health Behavior Change Clinic in Primary Care: An Interdisciplinary Partnership von Nyman, Scott J., Vogel, Mark E., Heller, Grant M., Hella, Jennifer R., Illes, Rose A., Kirkpatrick, Heather A.

Volltext

Selection of maize hybrids based on genotype × yield × trait (GYT) in different environments von Shojaei, S H, Mostafavi, K, Bihamta, M, Omrani, A, Bojtor, C, Illes, A, Szabo, A, Vad, A, Nagy, J, Harsányi, E, Mousavi, S M N

Volltext

Purinergic Signaling in Neuroinflammation

Volltext

Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer von RAO, S, CUNNINGHAM, D, ILLES, A, BELLY, R, PEREZ-RUIXO, J. J, PARK, Y. C, PALMER, P. A, DE GRAMONT, A, SCHEITHAUER, W, SMAKAL, M, HUMBLET, Y, KOURTEVA, G, IVESON, T, ANDRE, T, DOSTALOVA, J

Volltext

Analyzing the Effect of Intensive and Low-Input Agrotechnical Support for the Physiological, Phenometric, and Yield Parameters of Different Maize Hybrids Using Multivariate Statist... von Illes, A., Bojtor, C., Szeles, A., Mousavi, S. M. N., Toth, B., Nagy, J.

Volltext

Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: Analysis of the results of three clinical trials von Illes, A., Perjesi, L., Horvat-Karajz, K., Jeszenoi, N., Aradi, I., Singh, N.K., Mair, S.J., Kahan, Z.

Volltext

Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma von Simon, Zsofia, Barna, S., Miltenyi, Z., Husi, K., Magyari, F., Jona, A., Garai, I., Nagy, Z., Ujj, G., Szerafin, L., Illes, A.

Volltext

Effects of pituitary adenylate cyclase activating polypeptide on small intestinal INT 407 cells von Illes, A., Opper, B., Reglodi, D., Kerenyi, M., Czetany, P., Boronkai, A., Schafer, E., Toth, G., Fabian, E., Horvath, G.

Volltext

Effect of PACAP on Bacterial Adherence and Cytokine Expression in Intestinal Cell Cultures von Illes, A., Horvath, G., Schafer, E., Kerenyi, M., Karadi, O., Opper, B., Toth, G., Reglodi, D.

Volltext

Effects of Pituitary Adenylate Cyclase Activating Polypeptide in Human Proximal Tubule Cells Against Gentamicin Toxicity von Horvath, G., Reglodi, D., Czetany, P., Illes, A., Reman, Gy, Fekete, A., Toth, G., Laszlo, E., Opper, B.

Volltext

FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA von Hillmen, P., Byrd, J. C., Ghia, P., Kater, A. P., Chanan‐Khan, A., Furman, R. R., O'Brien, S., Yenerel, M. N., Illes, A., Kay, N., Garcia‐Marco, J. A., Mato, A., Pinilla‐Ibarz, J., Seymour, J. F., Lepretre, S., Stilgenbauer, S., Robak, T., Patel, P., Higgins, K., Sohoni, S., Jurczak, W.

Volltext

S196: ROPEGINTERFERON ALFA‐2B ACHIEVES PATIENT‐SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD‐PV/CONTINUATION‐PV STUDIES von Gisslinger, H., Klade, C., Georgiev, P., Krochmalczyk, D., Gercheva‐Kyuchukova, L., Egyed, M., Dulicek, P., Illes, A., Pylypenko, H., Sivcheva, L., Mayer, J., Yablokova, V., Empson, V., Krejcy, K., Hasselbalch, H., Kralovics, R., Kiladjian, J.‐J.

Volltext

P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP von Ghia, P., Pluta, A., Wach, M., Lysak, D., Simkovic, M., Kriachok, I., Illes, A., de la Serna, J., Dolan, S., Campbell, P., Musuraca, G., Jacob, A., Avery, E., Lee, J. H., Usenko, G., Wang, M. H., Yu, T., Jurczak, W.

Volltext

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b von Kiladjian, Jean-Jacques, Klade, Christoph, Georgiev, Pencho, Krochmalczyk, Dorota, Gercheva-Kyuchukova, Liana, Egyed, Miklos, Dulicek, Petr, Illes, Arpad, Pylypenko, Halyna, Sivcheva, Lylia, Mayer, Jiří, Yablokova, Vera, Krejcy, Kurt, Empson, Victoria, Hasselbalch, Hans C., Kralovics, Robert, Gisslinger, Heinz

Volltext

The importance of early immunotherapy in patients with faciobrachial dystonic seizures von Thompson, Julia, Bi, Mian, Murchison, Andrew G, Makuch, Mateusz, Bien, Christian G, Chu, Kon, Farooque, Pue, Gelfand, Jeffrey M, Geschwind, Michael D, Hirsch, Lawrence J, Somerville, Ernest, Lang, Bethan, Vincent, Angela, Leite, Maria I, Waters, Patrick, Irani, Sarosh R

Volltext

P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC‐C COMPARED TO IV DECI... von Geissler, K., Koristek, Z., Bernal del Castillo, T., Novák, J., Rodriguez Macias, G., Metzelder, S. K., Illes, A., Nagy, A., Mayer, J., Arnan, M., Keating, M.‐M., Krauter, J., Lunghi, M., Stefano Fracchiolla, N., Platzbecker, U., Santini, V., Sano, Y., Oganesian, A., Keer, H., Lübbert, M.

Volltext